Cooley advised Gamida Cell Ltd. on its $50 million initial public offering of 6,250,000 shares of common stock. Partners Div Gupta, Daniel Goldberg and Josh Kaufman led the Cooley team advising Gamida Cell.
BMO Capital Markets and RBC Capital Markets acted as joint book-running managers for the offering. Needham & Company and Oppenheimer acted as co-lead managers.
Gamida Cell is a clinical stage biopharmaceutical company leveraging its proprietary technology to develop cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The company’s shares now trade on the Nasdaq Global Market under the symbol “GMDA.”